Stockreport

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF Preclinical synergy data in prostate cancer models reinforces the promise of ORIC-944 as a potential best-in-class treatment for combinations with AR inhibitors First [Read more]